Blockchain Registration Transaction Record

GeoVax's Single-Dose MVA-X Vaccine Shows Durable Protection Against Mpox

GeoVax's MVA-X single-dose mpox vaccine shows durable protection against Clade I in preclinical studies, supporting a simplified outbreak response strategy.

This news matters because it could revolutionize mpox outbreak response. A single-dose vaccine would drastically simplify vaccination campaigns, especially in resource-limited settings where cold-chain and follow-up logistics are challenging. With mpox outbreaks becoming more frequent and Clade I associated with severe disease, a durable one-shot option could accelerate protection for at-risk populations and strengthen global biosecurity. Moreover, the findings highlight the critical role of CD8+ T cells in long-term immunity, potentially informing next-generation vaccine design beyond mpox.